How do you approach the management of borderline resectable pancreatic cancer in patients with superior mesenteric artery vs vein abutment ?

This is an area where treatment paradigms are in flux. If there is no vascular abutment our usual policy is resection followed by adjuvant treatment. With the augmented response rates being seen with FOLFOXIRI and gemcitabine + nab paclitaxel there is a better chance that tumor shrinkage off of vasc...